A detailed history of D. E. Shaw & Co., Inc. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 26,825 shares of PTGX stock, worth $1.05 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,825
Holding current value
$1.05 Million
% of portfolio
0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$33.72 - $47.33 $461,053 - $647,143
13,673 Added 103.96%
26,825 $1.21 Million
Q2 2024

Aug 14, 2024

SELL
$24.66 - $34.8 $554,554 - $782,582
-22,488 Reduced 63.1%
13,152 $455,000
Q1 2024

May 15, 2024

BUY
$21.79 - $32.15 $776,595 - $1.15 Million
35,640 New
35,640 $1.03 Million
Q2 2023

Aug 14, 2023

SELL
$18.02 - $29.36 $2.29 Million - $3.72 Million
-126,830 Reduced 63.57%
72,686 $2.01 Million
Q1 2023

May 15, 2023

BUY
$10.78 - $25.38 $123,754 - $291,362
11,480 Added 6.11%
199,516 $4.59 Million
Q4 2022

Feb 14, 2023

BUY
$7.36 - $11.17 $330,912 - $502,214
44,961 Added 31.42%
188,036 $2.05 Million
Q3 2022

Nov 14, 2022

BUY
$7.86 - $11.71 $1.12 Million - $1.68 Million
143,075 New
143,075 $1.21 Million
Q1 2022

May 16, 2022

SELL
$23.34 - $36.08 $1.01 Million - $1.56 Million
-43,286 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$17.63 - $37.1 $1.28 Million - $2.69 Million
-72,627 Reduced 62.66%
43,286 $1.48 Million
Q3 2021

Nov 15, 2021

SELL
$12.95 - $49.69 $1.71 Million - $6.58 Million
-132,322 Reduced 53.31%
115,913 $2.05 Million
Q2 2021

Aug 16, 2021

BUY
$25.57 - $44.88 $1.21 Million - $2.12 Million
47,255 Added 23.51%
248,235 $11.1 Million
Q1 2021

May 17, 2021

SELL
$19.02 - $31.15 $2.58 Million - $4.23 Million
-135,876 Reduced 40.34%
200,980 $5.21 Million
Q4 2020

Feb 16, 2021

SELL
$18.49 - $25.13 $3.53 Million - $4.8 Million
-190,977 Reduced 36.18%
336,856 $6.79 Million
Q3 2020

Nov 16, 2020

SELL
$15.19 - $22.4 $4.33 Million - $6.39 Million
-285,113 Reduced 35.07%
527,833 $10.3 Million
Q2 2020

Aug 14, 2020

BUY
$6.19 - $18.84 $3.3 Million - $10 Million
532,412 Added 189.79%
812,946 $14.4 Million
Q1 2020

May 15, 2020

SELL
$5.4 - $9.22 $809,908 - $1.38 Million
-149,983 Reduced 34.84%
280,534 $1.98 Million
Q4 2019

Feb 14, 2020

BUY
$4.69 - $13.45 $470,632 - $1.35 Million
100,348 Added 30.39%
430,517 $3.04 Million
Q3 2019

Nov 14, 2019

SELL
$9.41 - $16.56 $631,495 - $1.11 Million
-67,109 Reduced 16.89%
330,169 $3.97 Million
Q2 2019

Aug 14, 2019

BUY
$8.98 - $12.96 $1.25 Million - $1.81 Million
139,550 Added 54.15%
397,278 $4.81 Million
Q1 2019

May 15, 2019

BUY
$6.5 - $13.77 $1.55 Million - $3.28 Million
238,083 Added 1211.93%
257,728 $3.24 Million
Q4 2018

Feb 14, 2019

BUY
$6.3 - $10.44 $53,235 - $88,218
8,450 Added 75.48%
19,645 $132,000
Q3 2018

Nov 14, 2018

SELL
$6.82 - $11.26 $266,430 - $439,883
-39,066 Reduced 77.73%
11,195 $115,000
Q2 2018

Aug 14, 2018

BUY
$5.99 - $9.1 $301,063 - $457,375
50,261 New
50,261 $337,000
Q1 2018

May 15, 2018

SELL
$8.46 - $23.08 $264,383 - $721,273
-31,251 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$14.47 - $20.8 $452,201 - $650,020
31,251
31,251 $650,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.93B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.